Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Vertex Pharmaceuticals is diversifying beyond its dominant cystic fibrosis franchise, which currently accounts for 96% of product sales. The company is expanding into new therapeutic areas through promising pipeline candidates including pain relief drug Journavx, gene-editing therapy Casgevy (with CRISPR Therapeutics), kidney disease therapy inaxaplin, and recent acquisitions like Crinetics Pharmaceuticals ($10 billion) for endocrine disease treatments. With Q2 revenue of $3.33 billion (up 12% YoY) and raised full-year guidance, Vertex expects $500 million+ in 2026 sales from new products.